{"id":2617,"date":"2025-09-22T14:23:44","date_gmt":"2025-09-22T07:23:44","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=2617"},"modified":"2025-09-29T14:34:06","modified_gmt":"2025-09-29T07:34:06","slug":"abacavir-tablets","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/abacavir-tablets\/","title":{"rendered":"Abacavir Tablets"},"content":{"rendered":"

(Ph. Eur. 11.6 update)<\/p>\n

Action and use<\/strong><\/p>\n

Nucleoside reverse transcriptase inhibitor; antiviral (HIV).<\/p>\n

DEFINITION<\/h2>\n
Abacavir Tablets contain Abacavir Sulfate. They may be coated.<\/p>\n
The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n
Content of abacavir, C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O<\/p>\n}}}
95.0 to 105.0% of the stated amount.<\/p>\n
IDENTIFICATION<\/h2>\n
A. Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions in water.<\/p>\n
(1) Shake a quantity of powdered tablets containing the equivalent of 0.2 g of abacavir with 100 mL, filter and use the filtrate.<\/p>\n
(2) 0.23% w\/v of abacavir sulfate BPCRS.<\/p>\n
(3) 0.23% w\/v of abacavir sulfate BPCRS and 0.2% w\/v of zidovudine BPCRS.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
(a) Use precoated silica gel F_{254<\/sub> plates (Merck silica gel 60 F_{254<\/sub> plates are suitable).<\/p>\n}}
(b) Use the mobile phase described below.<\/p>\n
(c) Apply 10 \u03bcL of each solution.<\/p>\n
(d) Develop the plate to 12 cm.<\/p>\n
(e) After removal of the plate, dry it in air and immediately examine under ultraviolet light (254 nm).<\/p>\n
MOBILE PHASE<\/h3>\n
3 volumes of glacial acetic acid, 10 volumes of methanol and 90 volumes of dichloromethane.<\/p>\n
SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless the chromatogram obtained with solution (3) shows two clearly separated spots.<\/p>\n
CONFIRMATION<\/h3>\n
The chromatogram obtained with solution (1) shows a principal spot corresponding in position and size to the principal spot in the chromatogram obtained with solution (2).<\/p>\n
B. In the Assay, the chromatogram obtained with solution (1) shows a principal peak with the same retention time as the principal peak in the chromatogram obtained with solution (2).<\/p>\n
TESTS<\/h2>\n
Dissolution<\/h3>\n
Comply with the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n
TEST CONDITIONS<\/h4>\n
(a) Use Apparatus 2 and rotate the paddle at 75 revolutions per minute.<\/p>\n
(b) Use 900 mL of 0.1M hydrochloric acid as the medium at a temperature of 37\u00b0.<\/p>\n
PROCEDURE<\/h4>\n
(1) After 45 minutes withdraw a 10-mL sample of the medium and filter. Measure the absorbance of the filtered medium, diluted if necessary with 0.1M hydrochloric acid, at the maximum at 254 nm using 0.1M hydrochloric acid in the reference cell, Appendix II B.<\/p>\n
(2) Measure the absorbance of a solution containing 0.039% w\/v of abacavir sulfate BPCRS in 0.1M hydrochloric acid at the maximum at 254 nm using 0.1M hydrochloric acid in the reference cell.<\/p>\n
DETERMINATION OF CONTENT<\/h4>\n
Calculate the total content of abacavir, C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O, in the medium using the declared content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in abacavir sulfate BPCRS.<\/p>\n}}}}}}
LIMITS<\/h4>\n
The amount of abacavir released is not less than 75% (Q) of the stated amount.<\/p>\n
Related substances<\/h3>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions in 0.1% v\/v of orthophosphoric acid.<\/p>\n
(1) Shake a quantity of the powdered tablets containing the equivalent of 0.3 g of abacavir with 70 mL for 30 minutes, mix with the aid of ultrasound for 5 minutes; dilute to 100 mL and filter through a 0.45-\u03bcm filter (polyvinylidene fluoride is suitable). Dilute 1 volume of the filtrate to 20 volumes.<\/p>\n
(2) Dilute 1 volume of solution (1) to 100 volumes and further dilute 1 volume of the resulting solution to 5 volumes.<\/p>\n
(3) Dissolve 2.5 mg of abacavir for peak identification EPCRS in 10.0 mL.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
(a) Use a stainless steel column (15 cm \u00d7 3.9 mm) packed with octadecylsilyl silica gel for chromatography (5 \u03bcm) (Waters Symmetry Shield C18 is suitable).<\/p>\n
(b) Use gradient elution and the mobile phase described below.<\/p>\n
(c) Use a flow rate of 0.8 mL per minute.<\/p>\n
(d) Use a column temperature of 30\u00b0.<\/p>\n
(e) Use a detection wavelength of 254 nm.<\/p>\n
(f) Inject 10 \u03bcL of each solution.<\/p>\n
MOBILE PHASE<\/h4>\n
Mobile phase A 0.05% v\/v of trifluoroacetic acid.<\/p>\n
Mobile phase B methanol (85%).<\/p>\n\n\n\n\n\n\n\n\n\n\n
Time (Minutes)<\/td>\n Mobile phase A (% v\/v)<\/td>\n Mobile phase B (% v\/v)<\/td>\n Comment<\/td>\n<\/tr>\n
0-20<\/td>\n 95\u219270<\/td>\n 5\u219230<\/td>\n linear gradient<\/td>\n<\/tr>\n
20-35<\/td>\n 70\u219210<\/td>\n 30\u219290<\/td>\n linear gradient<\/td>\n<\/tr>\n
35-40<\/td>\n 10<\/td>\n 90<\/td>\n isocratic<\/td>\n<\/tr>\n
40-41<\/td>\n 10\u21920<\/td>\n 90\u2192100<\/td>\n column wash<\/td>\n<\/tr>\n
41-50<\/td>\n 0<\/td>\n 100<\/td>\n column wash<\/td>\n<\/tr>\n
50-51<\/td>\n 0\u219295<\/td>\n 100\u21925<\/td>\n column wash<\/td>\n<\/tr>\n
51-55<\/td>\n 95<\/td>\n 5<\/td>\n re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
SYSTEM SUITABILITY<\/h4>\n
The test is not valid unless, in the chromatogram obtained with solution (3):<\/p>\n
the chromatogram closely resembles the reference chromatogram supplied with abacavir for peak identification EPCRS;<\/p>\n
the resolution between the peaks due to abacavir and abacavir impurity D is at least 1.5.<\/p>\n
LIMITS<\/h4>\n
In the chromatogram obtained with solution (1):<\/p>\n
the area of any secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);<\/p>\n
the sum of the areas of all secondary peaks is not greater than 8 times the area of the principle peak in the chromatogram obtained with solution (2) (1.6%).<\/p>\n
Disregard any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).<\/p>\n
ASSAY<\/h2>\n
Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, in 0.1% v\/v of orthophosphoric acid.<\/p>\n
(1) Shake a quantity of the powdered tablets containing the equivalent of 0.1 g of abacavir with 70 mL for 30 minutes, dilute to 100 mL and filter. Dilute 1 volume of the filtrate to 5 volumes.<\/p>\n
(2) 0.023% w\/v of abacavir sulfate BPCRS.<\/p>\n
(3) Dissolve 2.5 mg of abacavir for peak identification EPCRS in 10 mL.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
The chromatographic conditions described under Related substances may be used.<\/p>\n
SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to abacavir and abacavir impurity D is at least 1.5.<\/p>\n
DETERMINATION OF CONTENT<\/h3>\n
Calculate the content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in the tablets from the chromatograms obtained using the declared content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in abacavir sulfate BPCRS.<\/p>\n}}}}}}
LABELLING<\/h2>\n
The quantity of active ingredient is stated in terms of the equivalent amount of abacavir.<\/p>\n
IMPURITIES<\/h2>\n
The impurities limited by the requirements of this monograph include those listed under Abacavir Sulfate.<\/p>\n","protected":false},"excerpt":{"rendered":"
(Ph. Eur. 11.6 update) Action and use Nucleoside reverse transcriptase inhibitor; antiviral (HIV). DEFINITION Abacavir Tablets contain Abacavir Sulfate. They may be coated. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of abacavir, C14H18N6O 95.0 to 105.0% of the stated amount. IDENTIFICATION A. Carry out the method for…<\/p>\n","protected":false},"author":5,"featured_media":2681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-2617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=2617"}],"version-history":[{"count":3,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2617\/revisions"}],"predecessor-version":[{"id":5550,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2617\/revisions\/5550"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/2681"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=2617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=2617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=2617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time (Minutes)<\/td>\n	Mobile phase A (% v\/v)<\/td>\n	Mobile phase B (% v\/v)<\/td>\n	Comment<\/td>\n<\/tr>\n
0-20<\/td>\n	95\u219270<\/td>\n	5\u219230<\/td>\n	linear gradient<\/td>\n<\/tr>\n
20-35<\/td>\n	70\u219210<\/td>\n	30\u219290<\/td>\n	linear gradient<\/td>\n<\/tr>\n
35-40<\/td>\n	10<\/td>\n	90<\/td>\n	isocratic<\/td>\n<\/tr>\n
40-41<\/td>\n	10\u21920<\/td>\n	90\u2192100<\/td>\n	column wash<\/td>\n<\/tr>\n
41-50<\/td>\n	0<\/td>\n	100<\/td>\n	column wash<\/td>\n<\/tr>\n
50-51<\/td>\n	0\u219295<\/td>\n	100\u21925<\/td>\n	column wash<\/td>\n<\/tr>\n
51-55<\/td>\n	95<\/td>\n	5<\/td>\n	re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n SYSTEM SUITABILITY<\/h4>\n The test is not valid unless, in the chromatogram obtained with solution (3):<\/p>\n the chromatogram closely resembles the reference chromatogram supplied with abacavir for peak identification EPCRS;<\/p>\n the resolution between the peaks due to abacavir and abacavir impurity D is at least 1.5.<\/p>\n LIMITS<\/h4>\n In the chromatogram obtained with solution (1):<\/p>\n the area of any secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);<\/p>\n the sum of the areas of all secondary peaks is not greater than 8 times the area of the principle peak in the chromatogram obtained with solution (2) (1.6%).<\/p>\n Disregard any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.1%).<\/p>\n ASSAY<\/h2>\n Weigh and powder 20 tablets. Carry out the method for liquid chromatography, Appendix III D, in 0.1% v\/v of orthophosphoric acid.<\/p>\n (1) Shake a quantity of the powdered tablets containing the equivalent of 0.1 g of abacavir with 70 mL for 30 minutes, dilute to 100 mL and filter. Dilute 1 volume of the filtrate to 5 volumes.<\/p>\n (2) 0.023% w\/v of abacavir sulfate BPCRS.<\/p>\n (3) Dissolve 2.5 mg of abacavir for peak identification EPCRS in 10 mL.<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/h3>\n The chromatographic conditions described under Related substances may be used.<\/p>\n SYSTEM SUITABILITY<\/h3>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to abacavir and abacavir impurity D is at least 1.5.<\/p>\n DETERMINATION OF CONTENT<\/h3>\n Calculate the content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in the tablets from the chromatograms obtained using the declared content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in abacavir sulfate BPCRS.<\/p>\n}}}}}} LABELLING<\/h2>\n The quantity of active ingredient is stated in terms of the equivalent amount of abacavir.<\/p>\n IMPURITIES<\/h2>\n The impurities limited by the requirements of this monograph include those listed under Abacavir Sulfate.<\/p>\n","protected":false},"excerpt":{"rendered":" (Ph. Eur. 11.6 update) Action and use Nucleoside reverse transcriptase inhibitor; antiviral (HIV). DEFINITION Abacavir Tablets contain Abacavir Sulfate. They may be coated. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of abacavir, C14H18N6O 95.0 to 105.0% of the stated amount. IDENTIFICATION A. Carry out the method for…<\/p>\n","protected":false},"author":5,"featured_media":2681,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-2617","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=2617"}],"version-history":[{"count":3,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2617\/revisions"}],"predecessor-version":[{"id":5550,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/2617\/revisions\/5550"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/2681"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=2617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=2617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=2617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

MOBILE PHASE<\/h3>\n3 volumes of glacial acetic acid, 10 volumes of methanol and 90 volumes of dichloromethane.<\/p>\n

SYSTEM SUITABILITY<\/h3>\nThe test is not valid unless the chromatogram obtained with solution (3) shows two clearly separated spots.<\/p>\n

TESTS<\/h2>\n

Dissolution<\/h3>\nComply with the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n

TEST CONDITIONS<\/h4>\n(a) Use Apparatus 2 and rotate the paddle at 75 revolutions per minute.<\/p>\n(b) Use 900 mL of 0.1M hydrochloric acid as the medium at a temperature of 37\u00b0.<\/p>\n

DETERMINATION OF CONTENT<\/h4>\nCalculate the total content of abacavir, C14<\/sub>H18<\/sub>N6<\/sub>O, in the medium using the declared content of C14<\/sub>H18<\/sub>N6<\/sub>O in abacavir sulfate BPCRS.<\/p>\n

LIMITS<\/h4>\nThe amount of abacavir released is not less than 75% (Q) of the stated amount.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h3>\nThe chromatographic conditions described under Related substances may be used.<\/p>\n

SYSTEM SUITABILITY<\/h3>\nThe test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to abacavir and abacavir impurity D is at least 1.5.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\nCalculate the content of C14<\/sub>H18<\/sub>N6<\/sub>O in the tablets from the chromatograms obtained using the declared content of C14<\/sub>H18<\/sub>N6<\/sub>O in abacavir sulfate BPCRS.<\/p>\n

LABELLING<\/h2>\nThe quantity of active ingredient is stated in terms of the equivalent amount of abacavir.<\/p>\n

MOBILE PHASE<\/h3>\n
3 volumes of glacial acetic acid, 10 volumes of methanol and 90 volumes of dichloromethane.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless the chromatogram obtained with solution (3) shows two clearly separated spots.<\/p>\n

Dissolution<\/h3>\n
Comply with the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n

TEST CONDITIONS<\/h4>\n
(a) Use Apparatus 2 and rotate the paddle at 75 revolutions per minute.<\/p>\n
(b) Use 900 mL of 0.1M hydrochloric acid as the medium at a temperature of 37\u00b0.<\/p>\n

DETERMINATION OF CONTENT<\/h4>\n
Calculate the total content of abacavir, C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O, in the medium using the declared content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in abacavir sulfate BPCRS.<\/p>\n}}}}}}

LIMITS<\/h4>\n
The amount of abacavir released is not less than 75% (Q) of the stated amount.<\/p>\n

CHROMATOGRAPHIC CONDITIONS<\/h3>\n
The chromatographic conditions described under Related substances may be used.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to abacavir and abacavir impurity D is at least 1.5.<\/p>\n

DETERMINATION OF CONTENT<\/h3>\n
Calculate the content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in the tablets from the chromatograms obtained using the declared content of C_{14<\/sub>H_{18<\/sub>N_{6<\/sub>O in abacavir sulfate BPCRS.<\/p>\n}}}}}}

LABELLING<\/h2>\n
The quantity of active ingredient is stated in terms of the equivalent amount of abacavir.<\/p>\n